TREATMENT OUTCOMES FOR CHILDREN WITH ANXIETY DISORDERS

焦虑症儿童的治疗结果

• 批准号: 6391456
• 负责人: Moira Ann Rynn
• 金额: $ 15.8万
• 依托单位: UNIVERSITY OF PENNSYLVANIA
• 依托单位国家: 美国
• 财政年份: 2000
• 资助国家: 美国
• 起止时间: 2000-08-02 至 2005-07-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/6391456
• 关键词: anxiety disorders; clinical research; clinical trials; emotions; human subject; human therapy evaluation; mental disorder chemotherapy; middle childhood (6-11); outcomes research; pediatrics; psychopharmacology; sertraline

This application proposes Moira A. Rynn, M.D. for a Mentored Patient-Oriented Research Career Development Award at the University of Pennsylvania. The aims of this program include: 1) to support my development into an independent research scientist; 2) to support and enhance my development as an investigator in anxiety disorders in children and adolescents; 3) to develop my ability to use my clinical experience to design and execute a protocol that will answer a proposed research question; and 4) to provide the groundwork for the preparation of an RO1 grant application based on the research performed during the award period. These aims will be accomplished through a structured four-part plan: 1) to complete a Master's of Science of Clinical Epidemiology, a program of formal academic courses and tutorials to enhance my research skills, under the supervision of Dr. Brian Strom; 2) to obtain research training and mentoring by a senior scientist who will serve as my sponsor (Karl Rickels, M.D.) as well as by a co-sponsor (Edna Foa, Ph.D) and collaborators (Elizabeth Weller, M.D., Irwin Lucki, Ph.D., John March, M.D., M.P.H., Brian Strom, M.D., M.P.H., and Philip C. Kendall, Ph.D., ABPP); 3) to participate in several ongoing psychopharmacological trials for anxiety and depression in both children and adults in the Mood and Anxiety Disorders Section; and 4) to design and execute an original clinical research treatment protocol. Children aged 8 to 12 years and 11 months who meet the diagnosis of generalized anxiety disorder, separation anxiety disorder, or anxiety disorder nos will enter a randomized, double-blind, placebo-controlled trial to evaluate the safety and efficacy of 50 mg sertraline per day (Pt N = 60). I also will evaluate the moderating effect the presence of parental psychopathology has on the child's level of impairment, onset of disorder and response to medication treatment. Families will be followed for one year to collect for further research.

本申请向医学博士 Moira A. Rynn 提议授予宾夕法尼亚大学以患者为导向的研究职业发展奖。 该计划的目标包括：1）支持我发展成为一名独立研究科学家； 2）支持和促进我作为儿童和青少年焦虑症研究者的发展； 3) 培养我利用临床经验设计和执行方案来回答所提出的研究问题的能力； 4) 为根据资助期间进行的研究准备 RO1 资助申请奠定基础。这些目标将通过一个由四部分组成的结构化计划来实现：1）在 Brian Strom 博士的监督下完成临床流行病学理学硕士学位，这是一个由正式学术课程和教程组成的项目，旨在提高我的研究技能； 2) 获得由高级科学家（Karl Rickels，医学博士）、联合资助者（Edna Foa，博士）和合作者（Elizabeth Weller，医学博士、Irwin Lucki，博士、John March，医学博士、公共卫生硕士、Brian Strom，医学博士、公共卫生硕士和 Philip）提供的研究培训和指导C·肯德尔， 博士，ABPP）； 3) 参加情绪和焦虑障碍科正在进行的几项针对儿童和成人焦虑和抑郁的精神药理学试验； 4) 设计并执行原创的临床研究治疗方案。符合广泛性焦虑症、分离焦虑症或焦虑症编号的 8 至 12 岁零 11 个月儿童将参加一项随机、双盲、安慰剂对照试验，以评估每天 50 毫克舍曲林的安全性和有效性（Pt N = 60）。 我还将评估父母精神病理学的存在对孩子的损伤程度、疾病发作和对药物治疗的反应的调节作用。 家庭将被跟踪一年，收集数据以进行进一步研究。